Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice

Pompilio Faggiano¹, Francesco Fattorilli², Anna Frisinghelli³, Lucrezia Piccioli⁴, Nicolò Dasseni¹, Maria Vittoria Silverii², Laura Albricci³, Giuseppe D’Ambrosio⁴, Rosaria Garri³, Luigi Esposito⁴, Francesco Giallauria⁴

¹Cardiology Unit, University and ASST Spedali Civili, Brescia; ²Department of Experimental and Clinical Medicine, University of Florence, Cardiac Rehabilitation Unit, Careggi University Hospital, Florence; ³Cardiology Rehabilitation Unit, ASST Rhodense, Milan; ⁴Department of Translational Medical Sciences, Internal Medicine Unit, “Federico II” University of Naples, Italy

Abstract

The present study aims at evaluating the achievement of blood pressure, lipid and blood glucose targets, healthy lifestyle changes and appropriate drug prescription/adherence in patients attending secondary prevention/CR ambulatory visit after index cardiovascular event in a time period ranging 1 to 5 year. At ambulatory visit, a predetermined set of data collection was used, including demographic data, cardiovascular risk factors and lifestyle habits, type and time of index event, current symptoms, physical sign, biochemistry and current medical treatment (including type and dosage). Cardiovascular risk profile (smoking habits, physical activity and body weight), secondary prevention goals (LDL-cholesterol, blood pressure, resting heart rate, glycated haemoglobin level) and the use of recommended drugs were also evaluated and categorized. Study population consisted of 800 patients [644 men (84.5%), aged 69±10.9 years]]. Cardiovascular index events were coronary artery bypass graft (CABG) (20%) ST segment elevation myocardial infarction (STEMI) (28%), non-ST segment elevation myocardial infarction (NSTEMI) (21%) and stable angina (13%) by unstable angina (13%) and stroke (5%). About 30% of patients was symptomatic (angina or dyspnoea) at the time of ambulatory visit. Major comorbidities were hypertension (73%), dyslipidaemia (64%) and diabetes (40%). More than 80% of patients achieved target levels for blood pressure. Patients that have participated to cardiac rehabilitation programmes after cardiovascular index event showed best achievement in blood pressure target (83.8% vs 76.8%, p=0.02). LDL-cholesterol target (<70 mg/dl) was achieved in about 2/3 of patients; HbA1c target (<7%) was achieved in 56.4% of diabetic population. About 75% of study cohort was treated with RAAS inhibitors, 85% with beta-blockers, 92% with statins and 87% with acetylsalicylic acid. All drugs were increasingly adopted from index event. Implementing secondary prevention guidelines into the ‘real world’ clinical practice in “late” interval from 1 to 5 years after a cardiovascular event improved risk factors control and appropriate drug prescription. Whether these improvements translated into prognostic advantages remains to be elucidated.

Introduction

Secondary prevention is the most critical intervention to be delivered after cardiovascular index event in order to reduce mortality or preventing a new subsequent event [1]. Evidence-based interventions include optimal medical therapy, achievement of blood pressure, lipid and blood glucose targets, and appropriate lifestyle changes [2,3].

During the last decades, secondary prevention programmes evolved from simple bedside consultations of a few minutes into professionally led multidisciplinary interventions within cardiac rehabilitation (CR) units devoted at preventing future cardiac events and slowing disease progression [3,4]. Cardiac rehabilitation strategies include comprehensive lifestyle interventions based on behavioural change models (i.e. quit smoking, healthy food choices, stress/anxiety management and exercise training), with predominant involvement of the patient in making self-related health decisions [5-9].

Cardiovascular risk factor management, aiming at reaching blood pressure, lipids and glucose targets, as well as the appropriate prescription and adherence to drugs, are now integral parts of this approach [10]. Psychological interventions targeted at supporting coping strategies, decreasing psychosocial risk factors and improving patients’ adherence to preventive interventions and behavioural changes, has become increasingly important [11,12].
However, in Europe, it is estimated that of eligible patients, only 14% to 35% of heart attack survivors and 31% of patients after coronary artery bypass surgery participate in secondary prevention programmes and that 70% of suitable patients do not receive dedicated secondary prevention interventions for risk factor reduction [13-15]. Conversely, in patients attending secondary prevention/CR programmes, few data are available regarding long-term achievement of cardiometabolic targets or appropriate drug prescription and adherence [6,7,16,17]. In fact, several studies previously assessed the status of secondary prevention in the first 12 months after index cardiovascular event [6,7,10]. On the other hand, there is a gap of knowledge on the control of risk factors beyond the first year after the first presentation of atherosclerotic disease. Accordingly, the present study aims at evaluating the secondary prevention strategy implementation (achievement of blood pressure, lipid and blood glucose targets, and healthy lifestyle changes and appropriate drug prescription/adherence) in patients enrolled in a time period ranging 1 to 5 years after index cardiovascular event.

**Patients and Methods**

From January 1st to April 30th 2018, 800 outpatients were recruited by the Secondary Prevention Units of Brescia and Passirana (ASST Rhodense). The study enrolled adult patients of both sexes with any clinical-instrumental manifestation of coronary artery disease (CAD) observed during routine follow-up visits in 2 different centres. The diagnosis of CAD was defined as: previous coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in elective or in urgent; previous ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI) regardless of revascularization; history of chest pain with positive stress perfusion myocardial scintigraphy imaging or with evidence of stenosis >70% of at least 1 coronary artery to coronary angiography. The patient was deemed eligible if the diagnosis of CAD was between 1 and 5 years before current evaluation.

During the clinical evaluation, a predetermined set of data collection was used, including demographic data, cardiovascular risk factors and lifestyle habits, type and time of index event, current symptoms, physical sign, biochemistry and current medical treatment (including type and dosage). Furthermore, cardiovascular risk profile (smoking habits, physical activity and body weight), secondary prevention goals (LDL-cholesterol, blood pressure, resting heart rate, glycated haemoglobin level) and the use of recommended drugs were evaluated and categorized. The therapeutic targets for blood pressure (<140/90 mmHg) refer to the current guidelines of the European Society of Cardiology [1]. Predefined therapeutic goals for LDL were set according to the European guidelines on dyslipidaemia: LDL-C levels <70 mg/dl for very high CV risk patients in secondary prevention [1,18]. Secondary prevention goal for glycated haemoglobin level was <7% [19]. The study was approved by the local Ethics Committee.

**Statistical analysis**

The results are presented in crude data and then divided by age, gender and diagnostic access category. Continuous variables were presented as mean ± standard deviation (SD); discrete variables as a percentage or proportions were appropriate. Comparisons between groups were performed by unpaired t test, chi-square test or Fischer’s exact test as required. Multivariate analysis (Model 1) was performed with blood pressure target achievement as dependent variable and age, sex, ejection fraction, dyslipidaemia, diabetes, obesity, index event (CABG, stable and unstable angina, NSTEMI, STEMI, PCI, stroke/TIA, atrial fibrillation), and blood pressure lowering therapy as independent variables. Multivariate analysis (Model 2) was performed with LDL target achievement as dependent variable and age, sex, ejection fraction, arterial hypertension, diabetes, obesity, index event (CABG, stable and unstable angina, NSTEMI, STEMI, PCI, stroke/TIA, atrial fibrillation), attendance to cardiac rehabilitation programmes and blood pressure lowering therapy as independent variables. All analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) with significance set at p<0.05.

**Results**

**Cardiovascular index event**

Study population consisted of 800 patients [644 men (84.5%), aged 69±10.9 years]. Table 1 shows anthropometrical, clinical and biochemical characteristics and cardiovascular index event of the study population. Cardiovascular index events were CABG (20%), NSTEMI (28%), STEMI (21%), stable angina (13%), unstable angina (13%) and stroke (5%). About 53% (n=429) of patients attended CR programmes. Clinical and drug therapy data were obtained in the whole population; lipid profile was obtained in 83% and glomerular filtration rate in about 50% of the study cohort.

The most common procedure was PCI (76.2%, in 12.1% at multiple site); and 20.1% of the study cohort underwent CABG. Notably, 15.6% had multivessel coronary artery disease. Overall, there were no significant gender-related differences in prevalence of index events, with the exception of NSTEMI and PCI (more frequent in women), and CABG (more frequent in men) (Table 1).

About 30% of patients (n=238, 77% males) was symptomatic at the time of ambulatory visit: 7% reported angina and 23% reported dyspnoea.

**Comorbidities and traditional cardiovascular risk factors**

Principal comorbidities and cardiovascular risk factors were reported in Table 2. Overall, 73% of patients had hypertension, 64% had dyslipidaemia and about 40% diabetes (Table 2). Twenty-nine percent of patients showed extra-coronary atherosclerosis (peripheral artery disease or carotid artery disease); 15.9% of study cohort had pacemaker or implanted cardioverter device (ICD) (Table 2). Notably, women showed higher prevalence of diabetes (48% vs 38.8%, p=0.02) and higher levels of Total-cholesterol (152.5±33.2 vs 140.0±31.6mg/dl, p=0.001) and LDL-cholesterol (79±28.8 vs 71.2±27.5mg/dl, p=0.004) compared to men, respectively (Table 2). Finally, women showed higher heart rate (67.5±10.5 vs 64.9±10.1 beats per minute, p=0.004) compared to men. About sixty-eight percent of the study population had eGFR ≥ 60 ml/min and 8.1% lower than 30 ml/min.

Data showed that 23.7% of the study population was still active smoker after cardiovascular event index; only 17.7% of patients never smoked in life and about 58.6% of patients quitted (Figure 1). Of note, women are still active smokers after acute index event compared to men (48.9% vs 18.8%, p=0.001, respectively) (Figure 1). Interestingly, there was no significant differ-
ences in smoking habits prevalence independent of time from index event (active smokers were 25.8% at 1 year; 13.3% at 2 years; 15.4% at 3 years; 25.3% at 4 years; 16.4% at 5 years from index event), confirming that smoking habits are very difficult to eradicate in cardiac patients.

Almost half of the study population was physically inactive: 45.7% of the study population performed moderate-intensity physical activity and only 2.7% was involved in vigorous activity (Figure 2). Notably, almost half of women cohort were sedentary (Figure 2).

**Target achievement**

Table 3 reported percentages of recommended targets according to International Guidelines based on history or clinical evaluation at the ambulatory visit.

More than 80% of patients achieved target levels for blood pressure (<140/90mmHg) (Table 3), independent of time of ambulatory visit from index event (generally ranging from 75 to 85% of target achievement). LDL-cholesterol target (<70mg/dl) was achieved in about 2/3 of patients. Interestingly, 76.5% of target achievement was obtained between 1 and 2 years from index event compared to longer periods (Table 3). LDL targets were achieved with a dose of simvastatin 10 mg in 12 patients, 20 mg in 34 patients and 40mg in 15 patients; with a dose of atorvastatin 10 mg in 17 patients, 20 mg in 75 patients, 40 mg in 115 patients and 80 mg in 38 patients; with a dose of rosuvastatin of 5 mg in 17 patients, 10 mg in 45 patients and 20 mg in 35 patients.

Patients that have participated to cardiac rehabilitation programmes after cardiovascular index event showed best achieve-

### Table 1. Anthropometrical, clinical characteristics and cardiovascular index event of the study population.

|                          | Total population (n=800) | Male (n=644, 80.5%) | Female (n=156, 19.5%) | p-value (M vs F) |
|--------------------------|-------------------------|---------------------|-----------------------|-----------------|
| Age (years)              | 69.±10.9                | 67.9±10.8           | 73.6±10.6             | <0.001          |
| Waist circumference (cm) | 100.5±12.7              | 101.3±12.5          | 98.4±13.7             | 0.173           |
| SBP (mmHg)               | 130.7±17.7              | 130.6±17.2          | 131.1±19.6            | 0.739           |
| DBP (mmHg)               | 76.2±9.5                | 76.5±9.3            | 75.8±10.4             | 0.593           |
| Heart rate (beats/min)   | 65.±10.3                | 64.9±10.1           | 67.5±10.5             | 0.004           |
| Total cholesterol (mg/dl)| 142.5±32.2              | 140.0±31.6          | 152.5±33.2            | 0.001           |
| LDL-cholesterol (mg/dl)  | 72.7±27.8               | 71.2±27.5           | 79.0±28.8             | 0.004           |
| HDL-cholesterol (mg/dl)  | 46.2±15.8               | 45.1±15.8           | 51.1±15.1             | 0.000           |
| Triglyceridemia (mg/dl)  | 127.9±64.6              | 129.8±67.0          | 120.3±52.8            | 0.119           |
| Glicemia (mg/dl)         | 115.2±37.9              | 114.2±37.2          | 119.6±40.4            | 0.125           |
| Creatinine (mg/dl)       | 1.3±1.2                 | 1.29±1.2            | 1.57±1.1              | 0.573           |
| Uric acid (mg/dl)        | 5.8±4.0                 | 5.9±3.4             | 5.6±5.8               | 0.474           |
| Stable angina            | 127 (15.9%)             | 101 (15.7%)         | 26 (16.7%)            | 0.763           |
| Unstable angina          | 128 (16.0%)             | 103 (16.0%)         | 25 (16.0%)            | 0.751           |
| NSTEMI                   | 200 (25.0%)             | 151 (23.4%)         | 49 (31.4%)            | 0.040           |
| STEMI                    | 253 (31.6%)             | 211 (32.8%)         | 42 (26.9%)            | 0.160           |
| Multisite atherosclerotic disease | 125 (15.6%) | 96/403 (23.8%) | 28/107 (27.1%) | 0.484 |
| CARG                     | 161 (20.1%)             | 144 (22.4%)         | 17 (10.9%)            | <0.001          |
| PCI                      | 610 (76.2%)             | 484 (75.1%)         | 126 (80.8%)           | 0.010           |
| Multisite PCI            | 97 (12.1%)              | 81 (12.6%)          | 16 (10.3%)            | 0.229           |
| LVEF (%)                 | 50.4±9.7                | 50.2±10.0           | 51.4±8.1              | 0.172           |

SBP, systolic blood pressure; DBP, diastolic blood pressure; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; CARG, coronary artery by-pass graft; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction.

### Table 2. Comorbidity and cardiovascular risk factors of the study population

|                          | Total population (n=800) | Male (n=644, 80.5%) | Female (n=156, 19.5%) | p-value (M vs F) |
|--------------------------|-------------------------|---------------------|-----------------------|-----------------|
| Stroke/transient ischemic attack | 36 (4.5%)              | 31 (4.8%)           | 5 (3.2%)              | 0.385           |
| Atrial fibrillation      | 67 (8.4%)               | 49 (7.8%)           | 18 (11.5%)            | 0.112           |
| PAD/carotid artery disease | 232 (29.0%)            | 191 (29.7%)         | 41 (26.3%)            | 0.405           |
| PMK/ICD                  | 126 (15.8%)             | 101 (15.7%)         | 25 (16.0%)            | 0.916           |
| Hypertension             | 584 (73.0%)             | 464 (72.4%)         | 120 (76.9%)           | 0.219           |
| Dyslipidemia             | 512 (64.0%)             | 418 (65.0%)         | 94 (60.2%)            | 0.748           |
| Diabetes                 | 318 (39.8%)             | 243 (37.7%)         | 75 (48.0%)            | 0.020           |
| Obesity                  | 130 (16.3%)             | 97 (15.7%)          | 33 (21.2%)            | 0.06            |
| Active smoking           | 127/538 (23.7%)         | 84/448 (18.8%)      | 43/88 (48.9%)         | <0.001          |

PAD, peripheral artery disease; PMK, pacemaker; ICD, implantable cardioverter defibrillator.
ment in blood pressure (83.8% vs 76.8%, \( p=0.02 \)) and in LDL target (67.5% vs 63.5%, \( p=0.05 \)). In patients with diabetes, HbA1c target (<7%) was achieved in 56.4% of diabetic population; target achievement was more frequent when ambulatory visit was up to 3 years after cardiovascular index event.

Notably, patients attending CR programmes were more likely at target for blood pressure (83% vs 76%, \( p=0.22 \)), and showed lower LDL cholesterol levels (69±24 vs 78±32 mg/dl, \( p=0.001 \)), respectively.

In Model 1, after adjusting for age, sex, ejection fraction, dyslipidaemia, diabetes, obesity, index event (CABG, stable and unstable angina, NSTEMI, STEMI, PCI, stroke/TIA, atrial fibrillation), and blood pressure lowering therapy, lower ejection fraction (\( \beta=-0.114, \ p=0.003 \)) and unstable angina as index event (\( \beta=0.094, \ p=0.017 \)), being not diabetic (\( \beta=-0.095, \ p=0.012 \)) and attending CR programmes (\( \beta=0.109, \ p=0.006 \)) were significantly associated to blood pressure targets achievement. In Model 2, after adjusting for age, sex, ejection fraction, arterial hypertension, diabetes, obesity, index event (CABG, stable and unstable angina, NSTEMI, STEMI, PCI, stroke/TIA, atrial fibrillation), attendance to cardiac rehabilitation programmes and statin therapy, being male (\( \beta=0.92, \ p=0.03 \)), non-obese (\( \beta=0.86, \ p=0.041 \)) and on statin therapy (\( \beta=0.143, \ p=0.001 \)) were significantly associated to LDL targets achievement.

**Drug therapy**

Drug therapy was evaluated according to type (class); index event and time to index event in total population. Data were reported in Table 4.

About 75% of study cohort was treated with RAAS inhibitors (49.8% with ACE-inhibitors, 24.1% with ATII receptor antagonists). Eighty-five percent was on beta-blockers, 92% on statins

### Table 3. Blood pressure, LDL-cholesterol and glycosylated haemoglobin (HbA1c) target achievement according to years from cardiovascular index event

|                          | 1          | 2          | 3          | 4          | 5          | Total      |
|--------------------------|------------|------------|------------|------------|------------|------------|
| Blood pressure target    |            |            |            |            |            |            |
| No                       | 5 (22.7%)  | 45 (17.0%) | 35 (21.3%) | 24 (16.4%) | 39 (19.7%) | 148 (18.6%)|
| Yes                      | 17 (77.3%) | 220 (83.0%)| 129 (78.7%)| 122 (83.6%)| 159 (80.3%)| 647 (81.4%)|
| Total                    | 22 (2.8%)  | 265 (33.3%)| 164 (20.6%)| 146 (18.4%)| 198 (24.9%)| 795        |
| LDL-cholesterol target (<70 mg/dl) |          |            |            |            |            |            |
| No                       | 4 (23.5%)  | 85 (38.1%) | 43 (32.8%) | 44 (34.4%) | 49 (30.7%) | 225 (33.6%)|
| Yes                      | 13 (76.5%) | 138 (61.9%)| 88 (67.2%) | 84 (65.6%) | 116 (69.3%)| 439 (66.2%)|
| Total                    | 17 (2.6%)  | 223 (33.6%)| 131 (19.7%)| 128 (19.3%)| 165 (24.8%)| 664        |
| HbA1c target (<7%)       |            |            |            |            |            |            |
| No                       | 19 (39.9%) | 4 (25.0%)  | 10 (41.7%) | 9 (75.0%)  | 6 (60.0%)  | 48 (43.6%) |
| Yes                      | 29 (60.1%) | 12 (75.0%) | 14 (58.3%) | 3 (25.0%)  | 4 (40.0%)  | 62 (56.4%) |
| Total                    | 48 (43.6%) | 16 (14.5%) | 24 (21.8%) | 12 (10.9%) | 10 (9.1%)  | 110        |

HbA1c, glycosylated haemoglobin (only for diabetic patients).

**Figure 1. Smoking habits in study population.**
and 87% on acetylsalicylic acid (Table 4). Interestingly, ACE-inhibitors were adopted in 34.8% at 1 year from index event up to 50.3% at 5 years. ATII receptor antagonists were adopted in about 30% of population at 1 year and at 5 years from index event; with a lower adoption at 2-4 years period after index event (ranging from 18 to 26%). Acetylsalicylic acid was increasingly adopted from index event (78.3% at 1 year after index event up to 87.4% at 5 years). Similarly, statins were increasingly adopted from index event (86.9% at 1 year after index event up to 93% at 5 years). A separate analysis was performed among high-dose statins users: Atorvastatin (40-80 mg OD) was adopted by 3% of study cohort at 12-24 months, 43.1% at 24-36 months; 18.2% at 36-48 months, 15.2% at 48-60 months and 20.5% at 60-72 months; Rosuvastatin (20-40 mg OD) was adopted by 5.8% of study cohort at 12-24 months, 23.2% at 24-36 months; 20.3% at 36-48 months, 18.8% at 48-60 months and 31.9% at 60-72 months. Proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors were not prescribed in 4 patients (0.5%), although criteria for prescription were satisfied. In this cohort, 7.4% of patients was on Ezetimibe (4.3% at 12-24 months up to 7.5% at 60-72 months), and 30.2% of them on dual antiplatelet therapy.

**Table 4. Drugs use according to years from cardiovascular index event.**

| Drugs                  | Total (%) | 1 Year (%) | 2 Year (%) | 3 Year (%) | 4 Year (%) | 5 Year (%) |
|------------------------|-----------|------------|------------|------------|------------|------------|
| ACE-inhibitors         | 398/800(49.8%) | 8/23 (34.8%) | 144/268 (53.7%) | 81/164 (49.4%) | 66/146 (45.2%) | 80/159 (50.3%) |
| ARBs                   | 193/800(24.1%) | 7/23 (30.4%) | 50/268 (18.7%) | 33/164 (20.1%) | 38/146 (26%) | 48/159 (30.2%) |
| Statins                | 735/800(91.9%) | 20/23 (86.9%) | 239/268 (89.2%) | 157/164 (95.7%) | 136/146 (93.1%) | 148/159 (93%) |
| Beta-blockers          | 679/800(84.9%) | 21/23 (91.3%) | 218/268 (81.3%) | 139/164 (84.8%) | 126/146 (86.3%) | 139/159 (86.8%) |
| Acetylsalicylic acid   | 696/800(87.0%) | 18/23 (78.3%) | 233/268 (86.9%) | 137/164 (83.5%) | 131/146 (89.7%) | 139/159 (87.4%) |

ACEs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers.

**Discussion**

The present study reported data on patients with different clinical presentation of CAD evaluated in an ambulatory setting in the time period ranging from 1 to 5 years after cardiovascular index event.

This study cohort likely represents the “real world” cardiac patients compared to the highly selected study population of randomized clinical trials. Notably, high mean age (70 years) and the presence of several comorbidities, usually considered exclusion criteria from randomized clinical trials, strongly characterized study cohort. Moreover, a relevant number of patients had extra-coronary localization of atherosclerosis (i.e., stroke, peripheral artery disease), chronic kidney disease, atrial fibrillation. In addition, about 15% of the study cohort had multivessel atherosclerotic CAD (diagnosed at angiography or history of multiple site PCI). This clinical complexity requires more accurate prognostic stratification together with more aggressive secondary prevention strategy. In fact, about one third of enrolled patients reported symptoms at the time of ambulatory visit, particularly dyspnoea, chest pain or
palpitations. In addition, although this study was not designed for outcome evaluation, about 14% of study population (data available on 510/800 patients) reported angina or acute heart failure decompensation during the 12 months period before ambulatory visit. These data support the need for a more structured follow-up even beyond the first year from index events, with strong attention both to achieving and maintaining secondary prevention targets. Cardiac rehabilitation programmes could represent the wiser strategy for significantly impact on long-term achieving and maintaining secondary prevention targets [6,7].

The study showed higher prevalence of traditional risk factors in this ‘real world’ population: more than 76% of the study cohort had hypertension, 64% had dyslipidaemia and 40% diabetes. In addition, patients referred to secondary prevention/cardiac rehabilitation units were usually older, had more comorbidity and multisite atherosclerotic disease. Such a clinical complexity underlies frail status, usually not well characterized in the setting of cardiac rehabilitation, although many studies have reported the measurement of frailty in patients with coronary syndromes in intensive care units or in cardiology wards, and others have highlighted the close link between frailty and chronic heart failure [20-22].

The present study documented a large use of RAAS inhibitors (75%), beta-blockers (85%), statins (91%) and acetylsalicylic acid (87%), according to secondary prevention Guidelines [1]. These data are in line with data from EUROASPIRE IV Registry [23,24] suggesting a correct approach and adherence to secondary prevention strategies. Interestingly, about 30% of the study cohort was on dual antiplatelet therapy, even after the 12-month limit suggested by the Guidelines [25-30].

However, data from our registry did not allow for distinguishing whether dual antiplatelet therapy continuation should be ascribed to latest Guidelines suggesting a more aggressive approach [31]; or might be due to a newer coronary event determining dual antiplatelet therapy re-adoption.

Although there was correct adoption of recommended drug regimen, therapeutic targets were not achieved or maintained, mostly after 12 months from index event. In fact, only about 65% of patients was on target LDL (<70 mg/dl), although statins were widely used, even at high dose regimen. Among diabetics, about 55% of this cohort was on target HbA1c (<7%). Better results were obtained in blood pressure target achievement (80% of study population had values <140/90 mmHg) or resting heart rate (HR) target (70% of patients had resting HR <70 beats/min). However, it should be noted that blood pressure and HR were acquired only during the ambulatory visit, thus reducing long-term prognostic value of these indexes.

These “real world” data indicated a better cardiovascular risk factors control compared to the most recent EUROASPIRE IV registry [23,24] and to different world region registries [32-35]. Compared to European studies, data from the SURF registry enrolling Asian population showed a poorer control of several risk factors including physical inactivity (41-45%), overweight and obesity (59-78%), and ongoing smoking (15%) [32]. Impressive data came out from PURE study: the use of secondary preventive drug therapies in patients with known CHD or stroke in South Asia is low, with over 80% receiving none of the effective drug treatments [33]. Interestingly, only 46.5% of participants with hypertension were aware of the diagnosis, with blood pressure control among 32.5% of those being treated [35]. In the present study, the observed better ‘real world’ risk factors control is more likely due to the fact that patients are referred to secondary prevention/cardiac rehabilitation units where healthcare professionals are particularly skilled on secondary prevention management. In fact, more than 50% of the cohort has been enrolled to cardiac rehabilitation programme. Among this cohort, LDL-cholesterol and blood pressure targets were more frequently reached; and sedentary habits were less reported. These findings are in line with other studies suggesting that patients attending a cardiac rehabilitation programme were more likely to achieve lifestyle targets [23,36-39].

Overall, data suggest that secondary prevention management guidelines were correctly adopted translating into appropriate drug prescription and risk factors control even up to 5 years after cardiovascular index event. However, 16% of the study cohort was classified obese and 12% was active smoker; confirming that weight control and smoking are still the long-term great challenges of secondary prevention [7,8,40,41].

### Study limitation

Some limitation should be acknowledged. First, the relatively small sample size, predominantly men may limit conclusions; second, frailty was not evaluated. In addition, the relatively small sample size interfered with time-dependent analysis and did not allow to evaluate differences. Conversely, this study has several strengths since this cohort likely represent the “real world” cardiac patient (i.e. mean age 70 years and several comorbidities) compared to the highly selected cohorts of randomized clinical trials.

### Conclusions

Implementing secondary prevention guidelines into the “real world” clinical practice in “late” interval from 1 to 5 years after a cardiovascular event improved risk factors control and appropriate drug prescription. Whether these improvements translated into prognostic advantages remains to be elucidated.

### References

1. Piepoli MF, Corrà U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014;21:664-81.
2. Piepoli MF, Villani GQ. Lifestyle modification in secondary prevention. Eur J Prev Cardiol 2017;24:S101-7.
3. Piepoli MF, Corrà U, Dendale P, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur J Prev Cardiol 2016;23:1994-2006.
4. Pedretti RFE, Fattirolfi F, Griffio R, et al. Cardiac Prevention and Rehabilitation “3.0”: From acute to chronic phase. Position Paper of the Italian Association for Cardiovascular Prevention and Rehabilitation (GICR-IACPR). Monaldi Arch Chest Dis 2018;88:1004.
5. Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Society of Exercise Physiologists, the European Society of Cardiology, the World Society for Cardiovascular and Pulmonary Rehabilitation. Eur J Prev Cardiol 2016;23:1994-2006.

[Page 152] (Monaldi Archives for Chest Disease 2019; 89:1040)
Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol 2013;20:442-67.
6. Giannuzzi P, Temporelli PL, Marchioli R, et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med 2008;168:2194-204.
7. Giallauria F, Lucci R, D’Agostino M, et al. Two-year multi-comprehensive secondary prevention program: favorable effects on cardiovascular functional capacity and coronary risk profile after acute myocardial infarction. J Cardiovasc Med (Hagerstown) 2009;10:772-80.
8. Giallauria F, Paragliola T, Pilerci F, et al. Role of smokers in the household and of cardiac rehabilitation in smoking behaviour after acute myocardial infarction. Monaldi Arch Chest Dis 2005;64:110-5.
9. Giallauria F, Battimiello V, Veneziano M, et al. Psychosocial risk factors in cardiac practice. Monaldi Arch Chest Dis 2007;68:74-80.
10. Keenan J. Improving adherence to medication for secondary cardiovascular disease prevention. Eur J Prev Cardiol 2017;24:S29-35.
11. Pogosova N, Saner H, Pedersen SS, et al. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol 2015;22:1290-306.
12. Olsen SJ, Schirmer H, Wilsgaard T, et al. Cardiac rehabilitation and symptoms of anxiety and depression after percutaneous coronary intervention. Eur J Prev Cardiol 2018;25:1017-25.
13. Bjarnason-Wehrens B, McGee H, Zwisler AD, et al. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prev Rehabil 2010;17:410-8.
14. Clark AM, King-Shier KM, Duncan A, et al. Factors influencing referral to cardiac rehabilitation and secondary prevention programs: a systematic review. Eur J Prev Cardiol 2013;20:692-700.
15. Gallagher R, Neubeck L, Du H, et al. Facilitating or getting in the way? The effect of clinicians’ knowledge, values and beliefs on referral and participation. Eur J Prev Cardio. 2016;23:1141-50.
16. Greco A, Cappelletti ER, Monzani D, et al. A longitudinal study on the information needs and preferences of patients after an acute coronary syndrome. BMC Fam Pract 2016;17:136.
17. Griffio R, Ambrosetti M, Tramarin R, et al. Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey. Int J Cardiol.2013;167:1390-5.
18. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058.
19. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669-2701.
20. Vigorito C, Abreu A, Ambrosetti M, et al. Frailty and cardiac rehabilitation: A call to action from the EAPC Cardiac Rehabilitation Section. Eur J Prev Cardiol 2017;24:577-590.
21. Afifalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014;63:747-62.
22. Prescott E, Meindersma EP, van der Velde AE, et al. A European study on effectiveness and sustainability of current Cardiac Rehabilitation programmes in the Elderly: Design of the EU-CaRE randomised controlled trial. Eur J Prev Cardiol 2016;23:S27-40.
23. Gouveia K, Wood D, De Bacquer D, et al. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. Eur J Prev Cardiol 2018;25:1242-51.
24. Gouveia K, De Bacquer D, De Backer G, et al. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol 2016;23:2007-18.
25. Piepoli MF, Corrà U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014;21:664-81.
26. Piepoli MF, Corrà U, Benzer W, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010;17:1-17.
27. Vanhees L, De Sutter J, Geladas N, et al. Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I). Eur J Prev Cardiol 2012;19:670-86.
28. Vanhees L, Geladas N, Hansen D, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR, Part II. Eur J Prev Cardiol 2012;19:1005-33.
29. Vanhees L, Rauch B, Piepoli M, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular disease (Part III). Eur J Prev Cardiol 2012;19:1333-56.
30. Piepoli MF, Corrà U, Dendale P, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur J Prev Cardiol 2016;23:1994-2006.
31. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213-60.
32. Cooney M, Reiner Z, Shu W, et al. SURF - S URvey of Risk Factor management: first report of an international audit. Eur J Prev Cardiol 2014;2:813-22.

[Monaldi Archives for Chest Disease 2019; 89:1040] [page 153]
33. Gupta R, Islam S, Mony P, et al. Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study. Eur J Prev Cardiol 2015;22:1261-71.
34. Avezum A, Oliveira GBF, Lanas F et al. Secondary CV Prevention in South America in a community setting: The PURE study. Glob Heart 2017;12:305-13.
35. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013;310:959-68.
36. Bjarnason-Wehrens B, McGee H, Zwisler AD, et al. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prev Rehabil 2010;17:410-8.
37. Clark AM, King-Shier KM, Duncan A, et al. Factors influencing referral to cardiac rehabilitation and secondary prevention programs: a systematic review. Eur J Prev Cardiol 2013;20:692-700.
38. Snaterse M, Deckers JW, Lenzen MJ, et al. Smoking cessation in European patients with coronary heart disease. Results from the EUROASPIRE IV survey: A registry from the European Society of Cardiology. Int J Cardiol 2018;258:1-6
39. Gallagher R, Neubeck L, Du H, et al. Facilitating or getting in the way? The effect of clinicians’ knowledge, values and beliefs on referral and participation. Eur J Prev Cardiol 2016;23:1141-50.
40. Urbinati S, Olivari Z, Gonzini L, et al. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry. Eur J Prev Cardiol 2015;22:1548-56.
41. Peersen K, Munkhaugen J, Gulstad L, et al. The role of cardiac rehabilitation in secondary prevention after coronary events. Eur J Prev Cardiol 2017;24:1360-8.